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Abstract 
Magnetic resonance imaging (MRI) is a powerful medical diagnostic imaging modality for integrin 
targeted imaging, which uses the magnetic resonance of tissue water protons to display tissue 
anatomic structures with high spatial resolution. Contrast agents are often used in MRI to highlight 
specific regions of the body and make them easier to visualize. There are four main classes of MRI 
contrast agents based on their different contrast mechanisms, including T1, T2, chemical exchange 
saturation transfer (CEST) agents, and heteronuclear contrast agents. Integrins are an important 
family of heterodimeric transmembrane glycoproteins that function as mediators of cell-cell and 
cell-extracellular matrix interactions. The overexpressed integrins can be used as the molecular 
targets for designing suitable integrin targeted contrast agents for MR molecular imaging. Integrin 
targeted contrast agent includes a targeting agent specific to a target integrin, a paramagnetic agent 
and a linker connecting the targeting agent with the paramagnetic agent. Proper selection of 
targeting agents is critical for targeted MRI contrast agents to effectively bind to integrins for in 
vivo imaging. An ideal integrin targeted MR contrast agent should be non-toxic, provide strong 
contrast enhancement at the target sites and can be completely excreted from the body after MR 
imaging. An overview of integrin targeted MR contrast agents based on small molecular and 
macromolecular Gd(III) complexes, lipid nanoparticles and superparamagnetic nanoparticles is 
provided for MR molecular imaging. By using proper delivery systems for loading sufficient Gd(III) 
chelates or superparamagnetic nanoparticles, effective molecular imaging of integrins with MRI has 
been demonstrated in animal models. 
Key words: Magnetic resonance imaging (MRI); Gd(III) chelates; Superparamagnetic iron oxide 
nanoparticles; Integrin; RGD peptides. 
1. Introduction 
The  benefits  of  earlier  detection  of 
life-threatening  diseases  have  promoted  the  shift  of 
biomedical research into the realm of predictive and 
preventative medicine. Molecular imaging of disease 
related biomarkers, such as over-expressed integrins, 
provides valuable information for earlier disease di-
agnosis and evaluation of treatment response. Mag-
netic resonance imaging (MRI) is a powerful medical 
diagnostic imaging modality for soft tissue imaging. It 
does not employ ionizing radiation and provides ex-
cellent  whole-body  soft  tissue  contrast  with 
sub-millimeter resolution [1]. Contrast enhanced MRI 
has  the  potential  to  detect  the  disease  related  bi-
omarkers in correlation to their accurate anatomical 
localization. With proper targeted MR contrast agents, 
MRI can elucidate the molecular mechanisms respon-
sible for disease development and progression [2].  
Integrins  are  a  family  of  adhesion  molecules 
through which cells can attach to extracellular matri-
ces, to each other’s surface or to different cell types 
[3-4].  All  integrins  are  composed  of  a  transmem-
brane-type heterodimer that consist of an α chain and 
a  β  chain.  Many  physiological  processes,  including 
cell activation, migration, proliferation and differen-Theranostics 2011, 1 
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tiation, require direct contact between cells and the 
extracellular matrix [4]. Integrins play key roles in the 
regulation  of  normal  and  tumor  cell  migration  and 
survival.  For  example,  αvβ3  and  α5β1-integrins  have 
been shown to regulate angiogenesis, the formation of 
new vessels, which contributes to wound healing and 
pathological  development  of  solid  tumor  cancers 
[5-6].  Integrins  have  direct  effects  in  preventing 
apoptosis in cancer cells and mediating proangiogenic 
interactions between endothelial cells and extracellu-
lar matrix [7]. With such diverse roles in cell biology, 
integrins  have  become  attractive  targets  for  the  de-
velopment  of  integrin-based  diagnostic  agents  and 
therapeutic drugs for cancer treatment [4, 8-9]. 
The primary purpose of this review is to provide 
an  overview  of  targeted  MR  imaging  of  integrins, 
which begins with an explanation of the basic princi-
ples of MRI, followed by a short introduction of MR 
contrast agents, and then a preview of the design and 
development of integrin binding MRI contrast agents 
as well as their application in MRI.  
2. Magnetic resonance imaging 
MRI is a powerful diagnostic modality that uses 
the  magnetic  resonance  of  tissue  water  protons  to 
display tissue anatomic structures with high spatial 
resolution. The first MR image was published in 1973 
by Paul Lauterbur [10]. The first studies performed on 
humans  were  published  in  1977  [11]  and  the  first 
publication of using paramagneic MR contrast agents 
appeared in the early 1980s [12]. During the past few 
decades, the applications of MRI in clinical oncology 
have been rapidly expanding. Compared with other 
imaging  modalities,  such  as  positron-emission  to-
mography  (PET),  single-photon  emission  computed 
tomography (SPECT) and X-ray computed tomogra-
phy (CT), MRI is advantageous because it does not 
require  radioactive  tracers  or  expose  patients  to 
harmful ionizing radiation [13-15].  
Principles of MRI 
Magnetic  resonance  imaging  generates  tissue 
images by measuring the interaction between an ex-
ternal  magnetic  field  and  the  magnetic  moment  of 
water protons. A normal human adult has approxi-
mately 60 % of the body weight as water. Water pro-
tons have a magnetic moment and the orientations of 
the magnetic moments are random in the absence of 
an  external  magnetic  field  [16].  When  a  patient  is 
placed  in  a  MRI  scanner,  the  proton  magnetic  mo-
ments align either along (low energy) or against (high 
energy) the static magnetic field (B0) of the scanner 
and create a net magnetization pointing in the direc-
tion  of the main magnetic field of the scanner. The 
number of protons in the lower energy state is slightly 
higher than those in the higher energy field and the 
distribution is given by the Boltzmann equation (Eq. 
1).  
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                  ...(1) 
where N↑ and N↓ refer to the lower and higher 
energy  states  of  the  protons,  γ  is  the  proton  gyro-
magnetic ratio, B0 is the strength of the external mag-
netic field, h is the Planck’s constant, 6.626 ￗ 10-34 J·s, 
kB is the Boltzmann’s constant, 1.381 ￗ 10-23 J·K-1 and T 
is  the  system  temperature.  The  greater  number  of 
protons aligning with the external field creates a net 
magnetization  (M0),  which  consists  of  MZ  and  MX-Y 
components. This phenomenon is shown in Figure 1. 
The magnitude of the magnetization (M0) is propor-
tional to the external magnetic field strength, B0: [17] 
M0 = χB0                                   ...(2) 
where χ is known as the bulk magnetic suscep-
tibility.  
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Figure  1.  Schematic  illustration  of  the  change  of  net 
magnetization vector immediately after a radio-frequency 
pulse. Adapted from reference [17] with permission. 
 
Nuclear  magnetic  resonance  (NMR)  measures 
the change of the magnetization by applying radiof-
requency (RF) pulses. When an RF pulse is applied to 
create  an  oscillating  electromagnetic  field  (B1)  per-
pendicular to the main field, the protons absorb the 
energy and are temporarily excited to a higher energy 
state.  The  net  magnetization  rotates  away  from  its 
equilibrium orientation due to the absorption of RF 
energy. After the radio frequency pulse is switched 
off, the absorbed energy is released to the surround-
ings by two simultaneous events: 1) the recovery of 
the net magnetization toward the equilibrium orien-
tation, and 2) the dephase of the transverse magneti-
zation MX-Y. The first case is termed as the spin-lattice 
or  longitudinal  (T1)  relaxation  and  the  latter  is 
spin-spin or transverse (T2) relaxation.  Theranostics 2011, 1 
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The  rate  of  the  relaxations  is  governed  by  the 
relaxation times. The T1 relaxation time is defined as 
the time required after excitation for 63% of the lon-
gitudinal  magnetization  to  recover  to  its  original 
magnitude (Fig. 2). The process of T1 relaxation is de-
scribed by equation 3, 
 
1 T /
0 Z 1 M M
    e
                   ...(3) 
where Mz is the longitudinal magnetization, M0 
is the equilibrium magnetization, T1 is the longitudi-
nal relaxation time and τ is the time following a radio 
frequency pulse.  
 
 
Figure 2. T1 relaxation curve. The regrowth of longitudinal 
component of magnetization from the initial value Mz (0) to 
the equilibrium value M0. Adapted from reference [17] with 
permission. 
 
The T2 relaxation time is defined as the time re-
quired  after  excitation  for  the  magnetization  to  be 
reduced  to  37%  of  its  initial  value  via  irreversible 
processes (Fig. 3). This process is described by equa-
tion 4.   
 
2 T /
0 Y - X M M
   e
                            ...(4) 
where τ is the amount of time following a radio 
frequency  pulse  and  T2  is  the  transverse  relaxation 
time. Since the main magnetic field of MRI scanners is 
not perfectly homogenous, the inhomogeneity of the 
magnetic  field  also  causes  dephasing  of  individual 
magnetizations  of  protons,  resulting  in  more  rapid 
loss of transverse magnetization. The process is called 
T2* relaxation. 
As the magnetization recovers to the equilibri-
um, the absorbed energy that is released by these two 
processes is measured as electrical signals. The posi-
tion dependent frequency and phase are encoded into 
the transverse magnetization, and the measured sig-
nals are Fourier transformed to construct the spatial 
image [18]. Relaxation is fundamental to the contrast 
in an MR image because tissues have different relaxa-
tion characteristics. MR images are created based on 
the proton density, or T1 and T2 relaxation rates, and 
flow  and  diffusion  properties  in  different  tissues. 
Tissues with short T1 relaxation time give strong MR 
signal, resulting in bright images in T1-weighted MRI. 
Tissues with short T2 relaxation time produce weak 
MR signal, resulting in dark images in T2-weighted 
MRI. In some cases, the difference in relaxation rates 
between normal and diseased tissues is too small to be 
detected, resulting in no significant tissue contrast in 
MR images. Paramagnetic materials, including para-
magnetic metal ion chelates and nanomaterials, have 
been employed as contrast agents to enhance the im-
age  contrast  by  shortening  the  relaxation  times  of 
water protons [19-21].  
 
Figure 3. T2 relaxation curve. The decay of the magnitude 
of  the  transverse  magnetization  from  an  initial  value. 
Adapted from reference [17] with permission. 
 
MR contrast agent 
Contrast agents, also known as contrast media, 
are often used in medical imaging to highlight specific 
regions (e.g. the blood pool) of the body and make 
them easier to visualize. In MRI, intensive work in the 
development of  paramagnetic metal contrast agents 
has been reported in the past few decades [19, 22-24]. 
There  are  four  main  classes  of  MRI  contrast  agents 
based  on  their  different  contrast  mechanisms,  in-
cluding T1 [19], T2 [25], chemical exchange saturation 
transfer  (CEST)  agents  [26],  and  heteronuclear  con-
trast agents [27-29]. 
T1 contrast agents. T1 contrast agents shorten the 
longitudinal  relaxation  times  of  surrounding  water 
protons or increase the T1 relaxation rate (1/T1), and 
generate a positive image contrast [30]. The increase 
of T1 relaxation rate is linearly correlated to the con-
centration of the contrast agents:  
1/T1=1/T1,H2O+r1[M]                      ...(5) Theranostics 2011, 1 
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where 1/T1 is the relaxation rate of water pro-
tons with contrast agents, T1,H2O is the relaxation time 
of water protons, r1 is the relaxivity of contrast agents, 
and  [M]  is  the  concentration  of  contrast  agents.  A 
good T1 contrast agent is able to shorten T1 relaxation 
times  of  surrounding  water  protons  even  at  a  low 
concentration of the agent. This ability is measured by 
the  relaxivity,  r1,  of  the  contrast  agent.  Rapid  ex-
change between free water molecules and the water 
molecules bound to the contrast agents is required for 
the  T1  relaxation  process  and  high  relaxivity  of  the 
contrast agents. A contrast agent with higher T1 re-
laxivity  can  help  surrounding  water  protons  to  re-
cover to the equilibrium longitudinal magnetization 
more  rapidly,  producing  a  brighter  image  in 
T1-weighted MRI. Gd(III)-based chelates in Figure 4 
are the representative T1-weighted contrast agents.  
 
 
Figure 4. Schematic illustration of chemical structures of 
T1 contrast agents used in the clinical practice.  Adapted 
from reference [30] with permission. 
 
To date, stable Gd(III) chelates are the commonly 
used T1-weighted contrast agents in MRI because of 
their high paramanetism and favorable properties in 
term of relaxation enhancement [30]. Gd(III) has seven 
unpaired  electrons  and  their  symmetric  S-state  is 
closely  in  tune  with  the  proton’s  frequency  [19]. 
However, Gd(III) ion is highly toxic after administra-
tion as a free ion at low doses (10-20 µmol kg-1) [30]. 
Gd(III) ion needs to be complexed with chelating lig-
ands, e.g. cyclic or linear polyaminocarboxylic acids, 
forming  stable  complexes  in  the  design  and  devel-
opment of clinical MRI contrast agents [19]. The first 
MRI  contrast  agent  approved  for  clinical  use  was 
Gd-(diethylenetriamine  pentaacetate)  (Gd-DTPA, 
Magnevist®). Its clinical applications are initially fo-
cused on detecting the breakage of the blood  brain 
barrier  in  brain  tumors  [20].  Subsequently,  other 
DTPA derivatives and macrocyclic chelates, including 
Gd(DTPA-BMA)  (Omniscan®),  Gd-EOBDTPA  (Eo-
vist®),  Gd-BOPTA  (Multihance®),  Gd-DOTA  (Do-
tarem®) and Gd(HP-DO3A) (Prohance®), have been 
developed for clinical use, Fig. 4 [31-33]. In addition to 
Gd(III), Mn(II) has five unpaired electrons and is also 
paramagnetic.  Mn(II)  dipyridoxal  diphosphate 
(Mn-DPDP) was introduced as a hepatocyte-specific 
contrast agent in clinical practice [34]. These Gd(III) 
and Mn(II) complexes, generate brighter images and 
are the most commonly used T1 MRI contrast media. 
T2 contrast agents. T2 contrast agents shorten T2 
relaxation  times  of  the  surrounding  water  protons 
and  increase  transverse  relaxation  rates  (1/T2),  re-
sulting in negative image contrast. The enhanced T2 
relaxation rate of water protons is proportional to the 
concentration of contrast agents: 
 1/T2 = 1/T2,H2O + r2 [M]                     ...(6) 
where 1/T2 is T2 relaxation rate with the contrast 
agents, T2,H2O is the relaxation time of water protons, r2 
is the relaxivity of contrast agent, and [M] is the con-
centration  of  the  contrast  agents.  T2  relaxivity,  r2, 
measures the ability of contrast agents to affect the T2 
relaxation  rates.  T2  contrast  agents  affect  a  large 
number  of  water  molecules  by  producing  strong 
magnetic  susceptibility  [35].  Generally,  T2  contrast 
agents have the r2/r1 ratios of 10 or more, while T1 
contrast agents have r2/r1 ratios about 1~2 [19].  
The most commonly studied T2 contrast agents 
are  superparamagnetic  iron  oxide  (SPIO)  particles. 
Superparamagnetic  iron  oxide  nanoparticles  are  the 
first T2 contrast agent developed for clinical applica-
tions [36]. In 1996, injectable Feridex® (ferumoxides) 
was introduced as the world's first organ-specific MR 
imaging agent for liver imaging. It has been used to 
detect and evaluate liver lesions associated with an 
alteration  in  the  reticuloendothelial  system  [37]. 
Mono-dispersed superparamagnetic nanoparticles of 
Fe3O4, CoFe2O4 and MnFe2O4 with tunable diameters 
(3 to 20 nm) have been synthesized through the reac-
tion of metal acetylacetonate and 1,2-hexadecanediol 
(Fig. 5) [38]. The MnFe2O4 nanoparticles have higher 
magnetization and stronger MR contrast effects over 
Fe3O4 nanoparticles for in vivo cancer imaging [39-40]. 
Currently, most of T2 MRI contrast agents are still in 
the  stage  of  in  vitro  testing  or  preclinical  animal 
studies.  Several  key  issues,  including  toxicological Theranostics 2011, 1 
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effects, rapid excretion after imaging, long-term sta-
bility,  and  pharmacokinetics,  have  to  be  addressed 
prior  to  further  development  into  clinical  applica-
tions.  
 
 
Figure 5. TEM images of 6 nm Fe3O4 (left), 14 nm CoFe2O4 
(middle) and 14 nm MnFe2O4 nanoparticles (right). Adapted 
from reference [38] with permission. 
 
CEST  contrast  agents.  MR  contrast  can  also  be 
generated by an entirely different mechanism based 
on chemical exchange saturation transfer [41]. Chem-
ical exchange in NMR refers to any process in which a 
nucleus  exchanges  between  two  or  more  different 
chemical environments intramolecularly or intermo-
lecularly  [42].  In  1963,  Forsén  and  Hoffman  per-
formed  the  CEST  experiment  to  measure  proton 
transfer rates between salicylaldehyde and water[43]. 
CEST MRI contrast agents are designed based on the 
chemical  exchange  phenomena  between  bulk  water 
protons  (δ  =  4.78  ppm)  and  exchangeable  protons 
with a different chemical shift.  
The mechanism of CEST contrast agents is illus-
trated in Fig. 6. Bulk water protons are considered as 
pool A, and exchangeable protons of CEST contrast 
agents are considered as pool B. When the protons in 
pool B are irradiated with a soft pulse (low-power) at 
the resonance frequency of a nucleus of interest, the 
number  of  protons  aligned  against  the  field  is  in-
creased at the expense of those aligned with the field. 
Once the number of protons aligned with and against 
the  field  is  equal,  the  system  is  saturated.  The  net 
magnetization of pool B is zero and no NMR signal is 
observed.  Due  to  chemical  exchange,  a  saturated 
transfer from pool B to pool A takes place, leading to a 
decrease in signal of bulk water protons in pool A. 
Longitudinal  relaxation  returns  each  system  to  its 
equilibrium  distribution  of  protons  or  steady  state. 
The steady-state intensity (MA∞/MA0) of the protons in 
pool A is given by equation 7 [26, 35] : 
                  ...(7) 
where MA∞ is the signal intensity of pool A after 
prolonged presaturation of pool B protons, MA0 is the 
initial intensity of pool A, k2 is the unidirectional rate 
constant for the protons moving from pool A to pool 
B, and T1B is the longitudinal relaxation time of the 
protons in pool B. CEST images in MRI are darkened 
as  compared  to  images  obtained  without  a 
pre-saturation radio frequency pulse as the result of 
signal  loss  in  pool  A.  One  significant  advantage  of 
CEST agents over typical relaxation agents is that the 
CEST effect can be switched “on” and “off ” at will, 
since each response is uniquely related to the specific 
absorption frequency of their mobile protons [44].  
A representative CEST spectrum is shown in Fig. 
7 (right) using barbituric acid as an example. Howev-
er, the difference of the chemical shifts of protons in 
two pools is only a few ppm. In order to increase the 
sensitivity  of  CEST  MRI,  paramagnetic  CEST 
(PATACEST) agents have been developed based on 
some of the lanthanide chelates [44-47] agents provide 
larger chemical shifts (Fig. 7, left). The protons of wa-
ter molecules bound to Eu-DOTA-(glycine ethyl es-
ter)4 appear at about 50 ppm away from bulk water 
protons in the spectrum. Complexes of Tm3+ and Dy3+ 
are able to shift the bound water peaks to +500 ppm 
and -720 ppm, respectively [48]. The lager shift allows 
for faster exchange rates, resulting in the increase of 
imaging sensitivity [35]. However, the sensitivity of 
PARACEST agents is still below that of the conven-
tional Gd(III)-based relaxation agents and the amount 
of CEST agent required to produce significant water 
contrast is unrealistically high for clinical applications 
[49]. Several approaches to enhance the sensitivity of 
CEST  agents  have  been  proposed,  including  per-
fluorocarbon-filled  nanoparticles  [50]  entrapped 
within a liposomal vesicle [30, 51], as well as cationic 
polymer coupled with negatively charged lanthanide 
complex [52-53]. 
 
Figure 6. Schematic representations of the distribution of 
protons, aligned with and against the field (upper and lower 
energy levels) (top panel) and simulated NMR spectra (lower 
panel)  for  two  chemically  distinct  pools  of  protons  (left 
column), two pools after a saturation pulse has been applied 
to one pool (middle column), and for a system undergoing 
chemical exchange after a saturation pulse has been applied 
to one pool (right column). Adapted from reference [26] 
with permission. 
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Figure 7. The CEST spectra of barbituric acid (blue) and a 
Eu
3+ complex, Eu-DOTA-(glycine ethyl ester)4 (red). The 
CEST spectrum of barbituric acid is shown on the same 
scale as that of the Eu
3+ complex for comparative purposes. 
Adapted from reference [26] with permission. 
 
Heteronuclear  MRI  contrast  agents.  Pro-
ton-based MRI often suffers from interference or low 
contrast due to the background signals [27]. Relatively 
high concentration is required for contrast agents to 
generate  significant  relaxation  enhancement  [54]  or 
saturation  transfer  [55]  detectable  for  MRI[28].  Re-
cently, non-proton contrast agents based on  19F [27, 
56-57], and hyperpolarized  129Xe [28, 58-59] and  13C 
[29, 60] have been designed for MRI. These new con-
trast mechanisms based on the signal from nuclei of 
19F or hyperpolarized 129Xe and 13C have a potential to 
circumvent  the limitations of  1H-based MRI in con-
trast  sensitivity.  For  instance,  when  19F-containing 
contrast agents are introduced into living bodies, only 
the  19F signal of the contrast agents can be detected 
without  interference  from  the  background.  The  hy-
perpolarized 129Xe and 13C MRI is extremely sensitive 
to the hyperpolarized probes at low concentrations. 
However, hyperpolarized contrast agents suffer from 
short in vivo half-lives of the hyperpolarization of the 
agents. Nevertheless, new contrast mechanisms based 
on the heteronuclear contrast agents have a potential 
to expand the scope of MRI in clinical applications.  
3 Integrin Targeted MRI Contrast Agents 
The  currently  available  clinical  contrast  agents 
are  tissue  nonspecific  extracellular  contrast  agents 
[61]. These agents are not suitable for target-specific 
contrast  enhancement  in  both  clinical  and  experi-
mental  settings  [61-63].  Therefore,  there  have  been 
continuous efforts for developing more specific con-
trast agents that can offer more accuracy diagnostic 
imaging [20, 23-24, 61, 64]. Integrins have been used 
as the molecular targets for design and development 
of targeted MRI contrast agents.  
Integrins  are  an  important  family  of  heterodi-
meric transmembrane glycoproteins that function as 
mediators  of  cell-cell  and  cell-extracellular  matrix 
interactions. These heterodimeric membrane proteins 
are highly versatile adhesion receptors, consisting of a 
large chain (α) of about 1000 amino acids and a small 
chain (β) of about 750 amino acids [65]. A variety of α 
and β subunits assemble into at least 24 distinct in-
tegrins[3]. Integrins on the cell surface bind to certain 
proteins of extracellular matrix, including fibronectin, 
vitronectin,  fibrinogen,  collagen,  and  laminin.  The 
structure of α and β subunits of the integrin deter-
mines  which  protein  in  the  extracellular  matrix  to 
bind. However, the ligand-binding specificity of the 
integrins is promiscuous. One integrin can bind sev-
eral different ligands and several different integrins 
can  bind  to  the  same  ligand  [65].  For  exmple,  αvβ3 
integrin is the most promiscuous of all known integ-
rins  which  binds  to  vitronectin,  fibrinogen  and  fi-
bronectin, whereas α5β1 and αvβ3 integrins both bind 
to fibronectin. Integrins are expressed at a cell-type 
and stage specific manner. Examples of cell-type spe-
cific integrins are αIIbβ3 in platelets and α6β4 in epithe-
lial  cells.  They  recognize  specific  ligands  through 
short  amino  acid  sequences,  such  as  RGD  peptide 
(Arg-Gly-Asp) [66]. Some of the integrins are overex-
pressed in diseased tissues. For example, overexpres-
sion of αvβ3 integrin promotes angiogenesis of in tu-
mor proliferation. The overexpressed integrins can be 
used  as  the  molecular  targets  of  designing  suitable 
small  molecular  antagonists  as  therapeutics  and  di-
agnostics for the related diseases [4].  
Design of targeted MR contrast agents for mo-
lecular imaging of integrins 
A  targeted  contrast  agent  includes  a  targeting 
agent  specific  to  a  target  integrin,  a  paramagnetic 
agent and a linker connecting the targeting agent with 
the paramagnetic agent. Proper selection of targeting 
agents is critical for targeted MRI contrast agents to 
effectively bind to integrins for in vivo imaging. The 
commonly used targeting agents are monoclonal an-
tibodies, their fragments and small peptides. Mono-
clonal antibodies have high specificity for binding to a 
specific  target.  Genetically  engineered  and  human-
ized  antibodies  have  been  developed  to  minimize 
immune reactions in clinical applications [67-68]. The 
molecular  weight  of  monoclonal  antibodies  is  ap-
proximately  150  KDa  and  they  have  a  slow  blood 
clearance. Therefore, small size antibody fragments, 
such  as  Fab  (molecular  weight  ~  50  KDa)  and  sin-
gle-chain variable fragment (scFv, molecular weight ~ 
50 KDa), have been developed to facilitate penetration 
into target tissues and to improve targeting efficiency. 
Synthetic small peptides can also be used as targeting 
agents in targeted MRI contrast agents. They are less Theranostics 2011, 1 
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immunogenic and can be  readily synthesized. RGD 
peptide is one of commonly used targeting agents for 
design  of  targeted  imagin  agents  for  αvβ3-integrin 
[69-72].  
Stable Gd(III) chelates can be directly conjugated 
to the targeting agents in the design of targeted con-
trast agents. However, due to the low sensitivity of 
MRI and low concentration of the integrins in target 
tissues, such targeted contrast agents are not effective 
for imaging of intergins with MRI. Various carriers, 
including  polymers,  dendrimer,  liposomes  and  mi-
celles, have been used in the design of targeted con-
trast agents to deliver a sufficient amount of Gd(III) 
chelates at the targeted to generate detectable contrast 
enhancement by MRI. The Gd(III) chelates must re-
main  chelated  in  the  body  and  there  should  be  no 
detectable dissociation of the chelates. Dissociation of 
the chelates is undesirable because both the free metal 
and  free  ligands  are  generally  more  toxic  than  the 
complex. Superparamagnetic iron oxide nanoparticles 
can also be incorporated with targeting agents in the 
design of targeted contrast agents for integrins. Iron 
oxide  nanoparticles  often  generate  strong  magnetic 
susceptibility  and  are  relatively  sensitive  for 
T2-weighted MR molecular imaging. After their role 
of molecular imaging is fulfilled, the targeted agents 
should be excreted completely from the body within 
hours to  minimize toxicity associated with the con-
trast agents.  
In some cases, steric hindrance due to the close 
proximity  of  the  targeting  agents  to  the  contrast 
agents may inhibit effective binding of the targeting 
groups to the target sites. A linker is often used to 
circumvent  this  problem  in  designing  targeted  MR 
contrast agents. In addition, a suitable linker can also 
improve the aqueous solubility and relaxivities of the 
targeted  MR  contrast  agents.  Poly(ethylene  glycol) 
(PEG)  is  commonly  used  as  a  linker  because  of  its 
insert  biophysical  properties  and  good  biocompati-
bility [73]. Avidin-biotin system has a high binding 
affinity and is also used as a linker in designing tar-
geted MR contrast agents [28, 74-75].  
Since  blood  circulation  is  turbulent,  a  targeted 
contrast agent may have a short time period to en-
counter a target integrin and the binding between the 
targeted contrast agent and the integrin may not be 
strong enough to stop the motion of contrast agents, 
especially for the bigger size targeted agents, such as 
macromolecules  and  nanoparticles.  As  a  result,  the 
targeted agent may not be anchored to the target site. 
In the design of targeted MRI contrast agents to in-
tegrins, it is necessary to incorporate enough ligands 
into the agents to guarantee the adhesive power of the 
targeted agents [76]. The integrin targeted MR con-
trast agents should be inert substance for in vivo im-
aging. They should not have any pharmacological and 
immunological  activities  after  intravenously  admin-
istration. An ideal integrin targeted MR contrast agent 
should  be  non-toxic,  provide  strong  contrast  en-
hancement at the target sites and can be completely 
excreted from the body after MR imaging.  
Targeted MR contrast agents based on small 
molecular Gd(III) complexes  
Initial efforts to develop targeted MRI contrast 
agents  involve  direct  conjugation  of  a  signalling 
group  onto  an  antibody  or  a  peptide.  Cyclic  RGD 
peptide has a relatively high and specific affinity for 
αvβ3-integrin  over-expressed  in  nascent  endothelial 
cells  during  angiogenesis  in  various  tumor  types. 
Targeted contrast agent specific to αvβ3-integrin has 
been reported by conjugating table Gd-DOTA chelate 
to a cyclic RGD peptide [77]. The structure of a RGD 
targeted  contrast  agent  is  shown  in  Fig.  8  [77]. 
Gd(DOTA-RGD) has a higher longitudinal relaxivity 
than  Gd-DOTA  (Dotarem®)  because  of  slower  mo-
lecular tumbling after introduction of the RGD pep-
tide.  The  targeting  ability  of  Gd(DOTA-RGD)  for 
αvβ3-integrin  was  evaluated  with  the  hepatocellular 
carcinoma in H-ras12V transgenic mice. Specific en-
hancement  in  the  tumor  with  high  expression  of 
αvβ3-integrin has been observed in the tumor model 
(Fig. 9). 
 
 
 
 
 
Figure  8. The chemical structure of Gd-(DOTA-RGD). 
Adapted from reference [77] with permission.  
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Figure  9. MR T1-weighted images of mice with hepato-
cellular  carcinoma  before  (A,  C)  and  after  injection  of 
Gd(DOTA-RGD), (B) and c-(RGDyK)(D) 30 minutes prior 
the injection of Gd(DOTA-RGD). The color indicates the 
signal intensity according to the pseudocolor scale on the 
right. Adapted from reference  [77] with permission.  
 
 
Targeted MR contrast agents based on macro-
molecular Gd(III) complexes  
Conjugation  of  Gd(III)  chelates  to  macromole-
cules  increases  the  rotational  correlation  time  of  a 
contrast  agent,  resulting  in  increased  relaxivity  [19, 
78]. Biocompatible macromolecules have been used as 
the  carriers  to  conjugate  a  large  number  of  Gd(III) 
chelates  and  multiple  targeting  moieties  in  the  de-
velopment  of  integrin-specific  MRI  contrast  agents. 
The targeted macromolecular agents are able to im-
prove MRI sensitivity at the relatively low concentra-
tions of integrins in the targeted sites due to increased 
relaxivity and a large payload of Gd(III) chelates.  
An  N-(2-hydroxypropyl)methacrylamide 
(HPMA)  copolymer-(Gd-DOTA)-cyclic  RGD  conju-
gate  was  prepared  for  noninvasive  MR  imaging  of 
αvβ3  integrin  of  MDA-MB-231  breast  tumors  with 
quantitative MR T1-mapping [79]. HPMA copolymers 
are  water  soluble,  biocompatible  and 
non-immunogenic, and have been used as carriers for 
drug  delivery  [80-84].  The  structure  of  the  HPMA 
copolymers targeted MR contrast agent is shown in 
Fig. 10. The targeted contrast agent was synthesized 
by  free  radical  copolymerization  of  HPMA  and 
monomers containing the RGD peptide and Gd che-
lates using N, N’- azobisisobutyronitrile as the initia-
tor and 3-mercaptopropionic acid as a chain transfer 
agent.  The  T1  relaxivity  of  HPMA  polymer 
(Gd-DOTA)-RGD conjugate with a molecular weight 
of 43 KDa was 20.6 s-1mM-1 per Gd at 1.5 T. The RGD 
targeted  polymer  contrast  agents  resulted  in  more 
significant  reduction  of  T1  value  in  tumor  tissue  2 
hours after the injection in mice bearing MDA-MB-231 
tumors than the non-targeted contrast agent, Fig. 11. 
The  injection  of  RGD-  HPMA  copolymer  conjugate 
before that of the targeted agent blocked the binding 
of  the  targeted  contrast  agent  to  αvβ3-integrin  (Fig. 
11c). 
 
 
Figure  10.  Structure  of  HPMA  copoly-
mer–(Gd-DOTA)–RGDfK  conjugates.  HPMA: 
N-(2-hydroxypropyl)methacrylamide;  APMA-benzyl- 
DOTA:  aminopropyl-methacryl-amide-benzyl-DOTA; 
MA-GG-RGDfK N-methacryloylglycylglycyl-RGDfK.[77] 
 
A  cyclic  RGDfK  targeted  poly(L-glutamic  ac-
id)-cystamine-(Gd-DO3A) conjugate was reported to 
facilitate  excretion  of  Gd(III)  chelates  after  specific 
imaging of αvβ3-integrin (Fig. 12) [85]. Cystamine was 
used as a degradable spacer to allow gradual release 
of  Gd(III)  chelates  from  the  conjugate  via  disul-
fide-thiol exchange reaction by endogenous free thiols 
(e.g. cysteine and reduced glutathione) in plasma. The 
targeted contrast agent exhibited high binding affinity 
to human prostate carcinoma DU145 cell line. In vivo 
contrast enhanced MR imaging in tumor bearing mice 
showed  that  the  RGD  targeted  polymeric  agent  re-
sulted in more significant T1 reduction at tumor pe-
riphery in DU145 prostate cancer xenografts than in 
sarcoma SLK xenografts due to specific binding to the 
αvβ3-integrin.  
Dendrimers  are  highly  branched  macromole-
cules  with  well-defined  structures  and  sizes.  RGD 
peptide and Gd(III) chelates have been conjugated to Theranostics 2011, 1 
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polyamidoamine (PAMAM) to prepare targeted con-
trast agents targeting αvβ3 integrin in angiogenic ves-
sels [86]. An RGD targeted PAMAM conjugate con-
taining  both  Gd-DTPA  and  a  fluorescent  dye  was 
reported  for  both  contrast  enhanced  MRI  and  fluo-
rescence imaging [87]. In vitro fluorescence imaging 
demonstrated the binding of the agent to its molecular 
target. However, the in vivo biodistribution study us-
ing  111In-labeled  RGD  targeted  PAMAM  in  tu-
mor-bearing mice showed little tumor accumulation. 
In vivo MR molecular imaging was not pursued with 
the  targeted  contrast  agent  because  MRI  is  far  less 
sensitive than radionuclide detection [87]. 
 
 
 
Figure 11. Contrast enhanced axial MR images and T1-maps of mice bearing human breast cancer cell line (MDA-MB-231) 
xenografts  before  and  after  injection  of  HPMA  copolymer-(Gd-DOTA)  conjugate  (A),  HPMA  copoly-
mer-(Gd-DOTA)-RGDfK conjugate (B), and HPMA copolymer-(DOTA)-RGDfK conjugate followed by injection of HPMA 
copolymer–(Gd-DOTA)–RGDfK conjugate after 2 h (C). Comparison of T1 values at tumor sites at different time points 
(D). The polymers were injected intravenously at a dose of 0.03mmol-Gd/kg. The arrows point to the tumor. The color 
scales are reflective of T1-values. The arrival of the contrast reduces the T1-value of the tumor as seen by the color dif-
ferences and begins to normalize back to its original value after about 6 h. Adapted from reference [77] with permission. Theranostics 2011, 1 
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Figure 12. Synthetic scheme of biodegradable c(RGDfK) targeted poly(L-glutamic acid)-cystamine-(Gd-DO3A) conjugate 
(A). T1-maps  of mice bearing human prostate carcinoma DU145 (left flank) and Kaposi’s sarcoma SLK (right flank) xeno-
grafts  before  and  after  injection  of  the  c(RGDfK)  containing  PGA-cystamine-(Gd-DO3A)  conjugate  (B)  and 
PGA-cystamine-(Gd-DO3A) (C). Adapted from reference [77] with permission.  
 
Targeted MR contrast agents based on lipid na-
noparticles 
Liposomes are spherical and self-assembled bi-
layers  formed  by  one  or  more  lipids  with  an  inner 
aqueous phase [88]. Liposomes have been used as a 
platform  for  drug  delivery  and  molecular  imaging. 
Paramagnetic  chelates  or  salts,  including  Gd-DTPA 
chelates  [89].  MnCl2 [90],  Gd(DTPA-BMA)  [91]  and 
Gd-DO3A  [92],  have  been  encapsulated  inside  the 
liposomes  to  prepare  MRI  contrast  agents.  Integrin 
targeting moieties have been coupled to the surface of 
liposomal MRI contrast agents for contrast enhanced 
MR imaging of αvβ3 integrin expressed on cell surface 
[93].  An  αvβ3  integrin  specific  monoclonal  antibody 
was conjugated to paramagnetic liposomes as a tar-
geted contrast agent for MR imaging of tumor angio-
genesis  [94].  The  paramagnetic  polymerized  lipo-
somes, shown as the insert of Fig. 13, were conjugated 
with a monoclonal antibody specific to αvβ3 integrin 
(LM609) via the biotin-avidin linker. The LM609 an-
tibody-conjugated  paramagnetic  liposomes  (ACPLs) 
with a size of 300-350 nm contained 30% of Gd(III) 
chelate-labeled  lipid.  Tumor  contrast  enhancement 
was clearly observed in a rabbit model of squamous 
cell  carcinoma  (Vx2)  with  the  targeted  liposomes, 
while no significant enhancement was observed in the 
tumor  with  the  non-specific  liposomal  contrast 
agents.  The  immunohistochemical  staining  for  αvβ3 
integrin  in  the  tumor  margin  was  correlated  to  its 
adjacent section stained for ACPLs (Fig. 14a, b). The 
αvβ3-positive vessel density was also correlated well 
to the degree of MR signal intensity. Strong contrast 
enhancement was observed in the MR images of tu-
mor  tissues  with  the  high  density  of  αvβ3-positive 
vessels (Fig. 14c, d). RGD peptide was also conjugated 
to paramagnetic liposomes to develop targeted MRI 
contrast agent for specific imaging of the tumor an-
giogenic endothelium in cancer mouse model [95]. 
An  RGD  targeted  micellar  dual  imaging  agent 
containing  Gd-DTPA  and  a  quantum  dot  (QD)  has 
been reported for molecular imaging of tumor angi-
ogenesis based on αvβ3-integrin with optical imaging 
and MRI [96]. The RGD-targeted micelles were com-
posed  of  paramagnetic  Gd-DTPA-bis(stearylamide) 
on  the  micellar  surface  and  CdSe/ZnS  core/shell 
quantum dots in the hydrophobic core (Fig. 15). Sig-
nificant  contrast  enhancement  was  observed  at  the 
tumor  periphery  45  min  after  injection  of  the 
RGD-targeted  micellar  agent  in  MR  images  of  a 
mouse tumor model. The strong fluorescence signal in 
the  tumor  of  fluorescence  images  (Fig.  15J)  further 
confirmed  that  the  RGD-targeted  micelles  accumu-
lated in the tumor. Theranostics 2011, 1 
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Figure 13. T1 MR images of rabbit tumors before and 24 after injection of anti- αvβ3 (LM609) ACPLs. a) Coronal images of 
tumor in the right thigh muscle; b) axial images of a intramuscle tumor; c) coronal images of a subcutaneously implanted V2 
carcinoma; d) LM609 ACPLs improved visualization of a subcutaneous tumor; e) axial images of hyperintense intramuscle 
tumor with central necrosis and the post-contrast image with LM609 ACPLs; f) coronal image of tumor growing in left thigh 
muscle and minimal tumor enhancement at 24 h after injection of isotype-matched control ACPLs; g) axial images of a rabbit 
subcutaneous tumor and almost no enhancement 24 h after administration of avidin-conjugated control paramagnetic 
liposomes. Insert illustrates the structure of ACPL. Adapted from reference [94] with permission. 
 
 
 
Figure 14. The expression αvβ3 integrin and ACPL localization in tumor tissue sections. a) An immunohistochemical 
staining section for αvβ3 integrin from the tumor margin shown in Fig. 13a; b) An adjacent tissue section stained for ACPLs; 
c) A staining section showed a high density of stained αvβ3 positive vessels from the tumor with strong MR enhancement 
with the ACPLs; d) A staining section showing a relative paucity of αvβ3 positive vessels from the tumor with relatively weak 
MR enhancement with ACPLs. Adapted from reference [94] with permission. Theranostics 2011, 1 
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Figure 15. The schematic structure of αvβ3-integrin targeted micellar nanoparticles for optical and MR imaging (left) and 
MR and optical molecular imaging of tumor angiogenesis (right). T2-weighted images before the contrast agent was injected 
(a, e); T1-weighted images before (b, f) and 45 min after (c, g) the injection of the RGD targeted micellar imaging agent and 
color-coded signal enhancement in tumors (d, h). The arrows in (c, g) indicate bright regions in the periphery of the tumor. 
Bioluminescence image (i) and fluorescence image (j) of a nude mouse with a luciferase-expressing renal carcinoma tumor 
after injection of luciferin (i) and the targeted imaging agent (j). The signal colocalizes with a strong fluorescence signal (j) 
originating from intravenously administrated RGD-pQDs that are accumulated in the tumor. Adapted from reference [96] 
with permission. 
 
 
Targeted MR contrast agents based on super-
paramagnetic nanoparticles 
Targeted  MRI  contrast  agents  based  on  super-
paramagnetic  nanoparticles  have  been  reported  for 
T2-weighted MR imaging of integrins. A targeted T2 
MRI  contrast  agent,  c(RGDyK)-4-methylcatechol  la-
beled  monodispersed  Fe3O4  nanoparticles,  with  a 
diameter of approximately 8.4 nm was synthesized by 
thermal  decomposition  of  Fe(CO)5,  followed  by  air 
oxidation and conjugation with peptide [97]. The r2 
relaxivity of the c(RGDyK) targeted Fe3O4 nanoparti-
cles was 165 mM-1s-1, 60% increase over that  of the 
commercial Feridex® nanoparticles (104 mM-1s-1) with 
a similar core size. The integrin targeting specificity of 
c(RGDyK) targeted Fe3O4 nanoparticles was shown in 
U87MG human glioblastoma cell line with high αvβ3 
integrin  expression  in  comparison  with  MCF-7  hu-
man breast cancer cell line with low αvβ3 integrin ex-
pression. The results demonstrated that Fe uptake in 
U87MG cells was 5-fold  higher than that in MCF-7 
cells.  A  significant  MR  signal  decrease  (~42%)  was 
observed in T2-weighted MR images of the tumor in 
mice bearing U87MG xenografts after injection of the 
c(RGDyK) targeted Fe3O4 nanoparticles (Fig. 16A, B). 
The  competitive  study  in  the  presence  of  free 
c(RGDyK) peptide only resulted in less signal reduc-
tion (~15%) for the targeted agent (Fig. 16C). Prussian 
blue staining confirmed the accumulation of the tar-
geted Fe3O4 nanoparticles in the tumor tissue after the 
MR scan at 4 h post-injection (Fig.16 D). The presence 
of the free peptide significantly reduced Prussian blue 
staining in tumor tissue (Fig. 16 E). 
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Figure 16. Schematic illustration of coupling c(RGDyK) peptide to Fe3O4 nanoparticles (upper). Axial T2-weighted MR 
images of the U87MG tumors implanted in mice without nanoparticles (A), with injection of 300 μg of c(RGDyK)-MC-Fe3O4 
nanoparticles (B) and with the injection of c(RGDyK)-MC-Fe3O4 nanoparticles free c(RGDyK) (C). Prussian blue staining of 
U87MG tumors for c(RGDyK)-MC-Fe3O4 nanoparticles (D), both (RGDyK)-MC-Fe3O4 nanoparticles and free c(RGDyK) 
(E). High resolution TEM image of 4.5 nm MC-Fe3O4 nanoparticles (F). Adapted from reference [97] with permission. 
 
 
 
RGD targeted bi-functional imaging probes have 
also been developed based on iron oxide for molecu-
lar imaging of integrins with dual imaging modalities. 
Cyclic  RGD  peptide  and  64Cu-DOTA  have  been  in-
corporated onto the surface of iron oxide nanoparti-
cles for imaging of αvβ3-integrin with PET and MRI 
[98]. The targeted bifunctional imaging agent resulted 
in  strong  PET  signal  in  U87MG  xenografts  with 
overexpressed αvβ3-integrin in a mouse tumor model 
and  significant  tumor  contrast  enhancement  in 
T2-weighted  MRI.  An  RGD  targeted  bi-functional 
agent  containing  iron  oxide  nanoparticles  and  a 
near-infrared fluorescent (NIRF) dye IRDye800 have 
also been reported for imaging of αvβ3-integrin with 
fluorescence  imaging  and  MRI  [99].  Both  RGD  and 
IRDye800 were coupled onto iron oxide nanoparticles 
via a triblock copolymer coated on their surface (Fig. 
17a). Iron oxide nanoparticle core has a diameter of 
approximately  10  nm  (Fig.  17b).  An  amphiphilic 
PEGylated  triblock  copolymer  consisting  of  a  poly-
butylacrylate segment, a polyethylacrylate segment, a 
polymethacrylic  acid  segment  and  a  hydrophobic 
hydrocarbon side chain was coated onto the iron ox-
ide nanoparticles, forming a bilayered structure and 
rendering the nanoparticles water-soluble. IRDye800 
possesses  improved  tissue  penetration  ability  as 
compared to conventional fluorophores in the visible 
range. Approximately 10 IRDye800 molecules and 15 
RGD peptides were coupled onto each nanoparticle. 
The hydrodynamic size of the targeted agent was ap-
proximately 20 nm as determined by dynamic light 
scattering analysis. The r2 relaxivity of the agent was 
190 mm−1 s−1 (Fig. 17c,d). The targeted dual imaging 
agent resulted in strong fluorescence signal in U87MG 
tumor  tissue  in  the  fluorescence  images  than  the 
non-targeted  contrast  agent.  Correspondingly,  the 
targeted  agent  resulted  in  more  significant  T2  en-
hancement in the tumor tissue than the non-targeted 
agent in the T2-weighted images of the tumor bearing 
mice (Fig.  18). High sensitive PET and fluorescence 
imaging with the targeted duel imaging agents vali-
date the effectiveness of the targeted iron oxide na-
noparticles  in  T2  weighted  MR  imaging  of 
αvβ3-integrin overexpressed in tumor tissue. 
Recently,  cyclic(RGDfK)-targted  super- 
paramagnetic  polymeric  micells  (SPPM,  Fig.  19A) 
have been developed for sensitive molecular imaging 
of  αvβ3  integrin  in  cancer  with  MRI  using 
off-resonance  saturation  [100].  Hydrophobic, 
mono-dispersed SPIO with a diameter ~9.9 nm were Theranostics 2011, 1 
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encapsulated inside of the micelles, and the peptide 
was  attached  onto  the  micelles’  surface.  The  final 
diameter of SPPM particles was about 75 nm deter-
mined  by  TEM  (Fig.  19C).  The  mechanism  of 
off-resonance saturation (ORS) is similar to CEST, and 
a  presuturation  pulse  can  be  applied  to  turn 
“ON”/”OFF” the contrast agents as desired. The dif-
ference  of  the  ORS  is  that  it  presaturates  at  an 
off-resonance frequency position away from the bulk 
water, while a specific exchangeable proton frequency 
is presaturated for CEST. In the absence of SPPM, the 
presaturation radiofrequency pulse has little effect on 
the signal intensity of SPPM-free water (Fig. 19B, top). 
In the presence of SPPM, the RF pulse can saturate a 
larger  volume  fraction  of  water  molecules  due  to 
proton relaxation by SPPM, leading to a considerable 
decrease in signal intensity (Fig.  19B, bottom). ORS 
contrast can be significantly amplified because of the 
rapid diffusion of water molecules [101]. Significant 
peak  broadening  was  observed  with  increasing  Fe 
concentrations, as shown by 1H-nuclear MR spectra of 
aqueous solutions containing different concentrations 
of SPPM particles in Fig. 19D.  
 
 
 
 
Figure 17. a) Schematic illustration of dual-modality RGD targeted iron oxide nanoparticles containing IRDye800 for 
tumor ανβ3 integrin imaging. b) TEM of the 10 nm iron oxide nanoparticles. c) T2-weighted phantom images of targeted agent 
at increased iron concentrations. d) 1/T2 vs. Fe concentration plot of the targeted agent. Adapted from reference [99] with 
permission. Theranostics 2011, 1 
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Figure 18. a) MR images of U87MG tumor-bearing mice injected with the RGD targeted dual agent (RGD-TPIO) and the 
nontargeted agent (TPIO) at a dose of 10 mg Fe/kg. The images were taken both coronally and transversely before and 4 h 
after particle injection. b) Optical imaging of U87MG tumor-bearing mice injected with RGD-TPIO and TPIO. The images 
were acquired 4 h hh h post injection. Adapted from reference [99] with permission.  
 
 
Figure 19. Cancer molecular imaging with cRGD-targeted SPPM and off-resonance saturation (ORS) MRI. A, schematic 
illustration of a cRGD-encoded SPPM and its targeting to αvβ3-integrin expressing endothelial cells in the tumor vasculature. 
B, mechanism of SPPM-induced ORS contrast. Presaturation RF pulse results in significant decrease in signal intensity in 
SPPM(+) H2O over SPPM(-) H2O. C, TEM image of a representative SPPM sample. D, 1H-NMR (300 MHz) spectra of water 
containing different concentrations of SPPM (in [Fe]/μmol/L). Adapted from reference [100] with permission. 
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Molecular imaging of RGD targeted SPPM with 
ORS  MRI  was  demonstrated  in  mice  bearing  A549 
tumor xenografts (Fig. 20). As shown in Fig. 20A, ORS 
contrast images showed a significant enhancement in 
tumors by cRGD-targeted SPPM 1 h after the injec-
tion. The CNR of the tumor over background muscle 
tissue was 10.7, which was larger than that of control 
groups injected with non-targeted SPPM and a mix-
ture of free RGD with RGD targeted SPPM (Fig. 20B).  
Prussian blue staining showed more accumula-
tion of SPPM in tumor vasculature for cRGD-targeted 
SPPM than the controls (Fig. 20A). The cRGD-targeted 
SPPM  showed  more  rapid  blood  clearance  than 
cRGD-free  SPPM  injected  over  24  hours  (Fig.  20C). 
Significantly  higher  tumor  accumulation  was  ob-
served for the cRGD-targeted SPPM than the controls 
1 hour after administration of the SPPMs (Fig. 20D). 
ORS  MRI  with  the  targeted  SPPM  showed  much 
higher sensitivity for imaging of αvβ3 integrin in an-
giogenic tumors than traditional T2*-weighted MRI. 
 
 
 
 
Figure  20. Proton density-weighted MR  images (PD-w) and  ORS MR images of  αvβ3 integrin in tumor tissue  with 
cRGD-targeted SPPM, cRGD-free SPPM, and a mixture of cRGD-encoded SPPM with free cRGD peptide in mice bearing 
A549 tumor xenografts (6 mg Fe/kg, free peptide 18 molar excess), and Prussian blue staining showing Fe presence from 
SPPM samples in tumor tissues (A). Comparisons of CNRs of ∆ORS images of tumor xenograft (n = 4) injected with 
cRGD-encoded SPPM, cRGD-free SPPM, and a mixture of cRGD-encoded SPPM with free cRGD peptide (B). Plasma 
concentration versus time for cRGD-encoded SPPM and cRGD-free SPPM (C). Biodistribution (n = 3) of cRGD-encoded 
SPPM, cRGD-free SPPM, and cRGD-encoded SPPM coinjected with free cRGD 1 h after i.v. administration. The asterisks (* 
in B and ** in D, inset) indicate statistical significance (P ≤ 0.05) between the SPPM group of interest and cRGD-targeted 
SPPM based on the Student’s t test. Adapted from reference [100] with permission. 
 
 
 
4. Conclusion 
MRI  is  clinical  diagnostic  imaging  modality 
without ionizing radiation and visualizes soft tissues 
with high spatial resolution. Contrast enhanced MR 
imaging has potential to visualize the over-expression 
of integrins in pathological tissues for accurate diag-
nosis  and  evaluation  of  therapeutic  efficacy.  Unfor-
tunately, MRI in molecular imaging is limited by its 
relatively  low  sensitivity.  Various  targeted  contrast 
agents have been designed and prepared for molecu-
lar imaging of integrins with MRI. By using proper 
delivery systems for loading sufficient Gd(III) chelates 
or superparamagnetic nanoparticles, effective molec-
ular imaging of integrins with MRI has been demon-
strated in animal models.  Theranostics 2011, 1 
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Sensitivity of contrast enhanced MRI can be im-
proved  using  new  contrast  mechanisms,  including 
off-resonance  saturation  and  hyperpolarization.  The 
combination  of  MRI  with  complementary  imaging 
techniques such as fluorescence imaging may provide 
more  effective  imaging  of  integrins.  Clinical  devel-
opment of MR imaging of integrins can be achieved 
after the demonstration of the safety and effectiveness 
of the integrin-specific contrast agents. 
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